Notably, autoreactive CD4+ T cells were detected in ten out of ten non-COVID-19 patients with GBS, but in only two out of five post-COVID-19 patients with GBS (Extended Data Fig. 2c,d). This evidence concerns the gene CD4 and Guillain-Barre syndrome.